Bisphosphonate safety and efficacy in chronic kidney disease

Kidney International

Volumn 82, Issue 8, 2012, Pages 833-835

  Ott, Susan M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE PAIN; BONE TURNOVER; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DRUG ADMINISTRATION ROUTE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG SAFETY; ESOPHAGITIS; ESOPHAGUS CANCER; FEMUR FRACTURE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; JAW OSTEONECROSIS; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 84866987963     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.253     Document Type: Note

References (11)

1. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. K idney Int 2008; 74: 1 385-1 393.
2. Boonen S, Sellmeyer DE, Lippuner K et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. K idney Int 2008; 7 4: 6 41-6 48.
3. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007 ; 357: nihpa40967, doi:10.1056/NEJMe074941.
4. Markowitz GS, Fine PL, Stack JI et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 6 4: 281-289.
5. Rogers MJ, Crockett JC, Coxon FP et al. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011; 4 9: 3 4-4 1.
6. Shih AWY, Weir MA, Clemens KK et al. Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney Int 2012; 82: 903-908.
7. Hill JA, Goldin JG, Gjertson D et al. Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad Radiol 2002; 9: 1148-1152.
8. Toussaint ND, Lau KK, Strauss BJ et al. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 2010; 5 6: 5 7-6 8.
9. Hartle JE, Tang X, Kirchner HL et al. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. A m J Kidney Dis 2012; 59: 6 36-6 44.
10. Cannata-Andia JB, Roman-Garcia P, Hruska K. The connections between vascular calcification and bone health. Nephrol Dial Transplant 2011; 26: 3429-3436.
11. Bauer DC, Garnero P, Hochberg MC et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006; 21: 292-299.